Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPM31510 and Vitamin K in Recurrent High-Grade Glioma
NCT03020602Phase 1Completed
- Start
- Jan 2017
- Primary completion
- Apr 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial of ubidecarenone nanodispersion in glioma, glioblastoma (GBM), Gliosarcoma (GS) and 1 more. Started Jan 2017; status: completed.
02
Drugs
ubidecarenone nanodispersion
03
Conditions
gliomaglioblastoma (GBM)Gliosarcoma (GS)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT03020602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020602.